Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): A 2-year follow-up randomized controlled trial

Liver International

Volumn 33, Issue 2, 2013, Pages 244-254

  Yim, Hyung Joon ^a   Seo, Yeon Seok ^b   Yoon, Eileen L ^a   Kim, Chang Wook ^c   Lee, Chang Don ^c   Park, Sang Hoon ^d   Lee, Myung Seok ^d   Park, Choong Kee ^d   Chae, Hee Bok ^e   Kim, Moon Young ^f   Baik, Soon Koo ^f   Kim, Yun Soo ^g   Kim, Ju Hyun ^g   Lee, Jung Il ^h   Lee, Jin Woo ^h   Hong, Sun Pyo ⁱ   Um, Soon Ho ^b  

^a Korea University   (South Korea)

^b College of Medicine   (South Korea)

^c Uijeongbu St Mary's Hospital   (South Korea)

^d Hallym University   (South Korea)

^e Chungbuk National University Hospital   (South Korea)

^f Wonju Severance Christian Hospital   (South Korea)

^g Gachon University   (South Korea)

^h Inha University Hospital   (South Korea)

ⁱ GeneMarix Inc   (South Korea)

Author keywords

Adefovir; Chronic hepatitis B; Entecavir; Lamivudine; Resistance

Indexed keywords

ADEFOVIR; ENTECAVIR; LAMIVUDINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; THERAPY EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE;

ADENINE; ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B; HEPATITIS B, CHRONIC; HUMANS; IMMUNOASSAY; LAMIVUDINE; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME;

EID: 84872159453     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12036     Document Type: Article

References (31)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006; 43: S173-81.
3. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
4. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-96.
5. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-22.
6. Lee KS, Kim DJ. Management of chronic hepatitis B. Korean J Hepatol 2007; 13: 447-88.
7. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
8. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
9. Lampertico P, Vigano M, Manenti E, et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
10. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13.
11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2012; 57: 167-85.
12. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
13. Yim HJ. Hepatitis B virus genetic diversity and mutant. Korean J Hepatol 2008; 14: 446-64.
14. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut 2006; 55: 1488-95.
15. Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46: 2525-32.
16. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
17. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48: 99-108.
18. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
19. Han KH, Hong SP, Choi SH, et al. Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir Ther 2011; 16: 77-87.
20. Lee CH, Kim SO, Byun KS, et al. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough. Gastroenterology 2006; 130: 1144-52.
21. Ono Y, Onda H, Sasada R, et al. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res 1983; 11: 1747-57.
22. Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 2008; 134: 405-15.
23. Manolakopoulos S, Bethanis S, Koutsounas S, et al. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008; 27: 266-73.
24. Cooksley WG. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepat 2010; 17: 601-10.
25. Chung GE, Kim W, Lee KL, et al. Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Dig Dis Sci 2011; 56: 2130-6.
26. Ryu HJ, Lee JM, Ahn SH, et al. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol 2010; 82: 1835-42.
27. Sheng YJ, Liu JY, Tong SW, et al. Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J 2011; 8: 393.
28. Seto WK, Liu K, Fung J, et al. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. Antivir Ther. in press.
29. Ikeda F, Baba N, Takaguchi K, et al. Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance. J Med Virol 2012; 84: 1562-70.
30. Manolakopoulos S, Karatapanis S, Elefsiniotis J, et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57-63.
31. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008; 48: 88-98.